Type 1 diabetes: treatment

EBM Guidelines
May 17, 2021 • Completely updated
Pirjo Ilanne-Parikka

Table of contents

Extract

  • Insufficient or absent insulin production by the pancreatic beta cells can be compensated by administration of insulin preparations into the subcutaneous fat by injection or with an insulin pump.
  • The aim is to keep blood glucose levels as close to normal as possible, without creating disturbing or severe hypoglycaemias or wide daily fluctuations of glucose levels.
  • Patients can adjust the insulin dosage themselves based on self-monitoring of blood glucose and/or continuous glucose monitoring.
  • If target glucose values are not achieved with an appropriate multiple injection regimen, adequate guidance and continuous glucose monitoring, the suitability of insulin pump therapy should be considered together with the patient.
  • Blood pressure and blood lipids must also be well controlled.

Read full article of Type 1 diabetes: treatment

Search terms

Addison Disease, Algorithms, Aviation, Blood Glucose Self-Monitoring, Carbohydrates, Diabetes Mellitus, Diabetes Mellitus, Type 1, E10*, Endocrinology, Exercise, Hemoglobin A, Glycosylated, Hyperglycemia, Hypoglycemia, Hypoglycemia, Insulin, Insulin Infusion Systems, Insulin detemir, Insulin glargine, Insulin regimes, Insulin, Isophane, Insulin, Long-Acting, Internal medicine, Multiple injection regimes, R73, Sports, Travel, basal insulin, brittle diabetes, detemir, fasting blood glucose, glargine, insulin analogue, insulin injection techniques, insulin sensitivity, insulin treatment, insulin, neutral, morning hyperglycemia, multi-injection regimen, plasma glucose, three-injection regimen, very rapidly-acting insulin